Alnylam Pharmaceuticals Inc. (ALNY) is in the Pharma Industry

• Sort by
• View by Content Type

• Investing in miRNA: Beware the Hype, Follow the Money

  Ohad Hammer submits: The momentum in the microRNA miRNA field is continuing to build, as evidence that links this group of important genes to multiple diseases, from Alzheimer to diabetes, is constantly mounting. The adoption of miRNAs is further accelerated by the technological advancements in RNA-based therapies. Because miRNAs are...

  External links 2008-06-10

  Tags: Biotech, Alnylam Pharmaceuticals Inc., Isis Pharmaceuticals Inc.

• Alnylam Pharmaceuticals, Q1 2008 Earnings Call Transcript

  Alnylam Pharmaceuticals, Q1 2008 Earnings Call Transcript

  Earnings calls 2008-05-22

  Tags: Alnylam Pharmaceuticals Inc., Call Transcript, Earnings, Seeking Alpha, Financial Accounting, Finance

• Alnylam Pharmaceuticals Q4 2007 Earnings Call Transcript

  Alnylam Pharmaceuticals Q4 2007 Earnings Call Transcript

  Earnings calls 2008-04-07

  Tags: Alnylam Pharmaceuticals Inc., Call Transcript, Earnings, Seeking Alpha, Financial Accounting, Finance

Additional Resources

• Regulus Therapeutics Selected for Fierce 15 Top Biotech Companies

  CAMBRIDGE, Mass. & CARLSBAD, Calif. -- Regulus Therapeutics LLC, a joint venture between Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) formed to discover, develop, and commercialize microRNA miRNA therapeutics, announced today that it has been named to the annual FierceBiotech "Fierce 15" list, designating it as...

  Articles 2008-06-24

• Alnylam to Webcast Presentation at the 2008 Piper Jaffray Europe Conference

  CAMBRIDGE, Mass. -- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the 2008 Piper Jaffray Europe Conference on Wednesday, June 25, 2008, at 10:20 a.m. BST (5:20 a.m. ET) at the AndAZ London formerly the Great Eastern Hotel...

  Articles 2008-06-18

• Zacks Analyst Blog Highlights: Alnylam Pharmaceuticals, GlaxoSmithKline, American Axle, GM and Health Net

  CHICAGO -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Alnylam Pharmaceuticals (Nasdaq: ALNY), GlaxoSmithKline (NYSE: GSK), American Axle (NYSE: AXL),...

  Articles 2008-06-02

• Alnylam Announces Close of Investment and Expanded Agreement Related to the Tekmira-Protiva Business Combination

  - Agreement Expands Alnylam's Access to Key Technologies and Intellectual Property for Systemic Delivery of RNAi Therapeutics - CAMBRIDGE, Mass. -- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced the closing of its investment in and completion of its expanded agreement with Tekmira Pharmaceuticals Corporation...

  Articles 2008-06-02

• Tekmira Pharmaceuticals and Protiva Biotherapeutics Announce Completion of Business Combination

  Tekmira Pharmaceuticals Corporation ("Tekmira") (TSX: TKM) and Protiva Biotherapeutics Inc. ("Protiva") announced today that they have completed the business combination between the two companies. The combined company, which will retain the name Tekmira, will be a global leader in the field of RNA interference ("RNAi") therapeutics. As part of the...

  Articles 2008-06-02

• Isis to Receive $4.6 Million From Alnylam

  CARLSBAD, Calif., May 27 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. announced today that it will receive $4.6 million dollars from Alnylam Pharmaceuticals, Inc. as its portion of the upfront fees in the recently announced transaction between Takeda Pharmaceutical Company Limited and Alnylam. In addition, Isis has the...

  Articles 2008-05-27

• Alnylam and Takeda Form Strategic Worldwide Platform Alliance in RNAi Therapeutics

  - Alnylam Selects Takeda as its Sole Asian Strategic Partner and Obtains Options for 50-50 Development and Commercialization of Takeda RNAi Therapeutic Programs in U.S. Market - - Takeda Gains Access and Enablement to Alnylam's Leading RNAi Therapeutics Technology and Intellectual Property in Fields of Oncology and Metabolic...

  Articles 2008-05-27

• Alnylam to Webcast Conference Call to Discuss Takeda Alliance

  CAMBRIDGE, Mass. -- Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), announced today that the company will hold a conference call on Tuesday, May 27 at 8:30 a.m. ET to discuss its alliance with Takeda announced this morning. Conference Call Information The call may be accessed by dialing 800-329-9097 domestic...

  Articles 2008-05-27

• Alnylam and Collaborators Publish In Vivo Research on Validation of a Mammalian Host Gene Involved in Malaria Infection and on the Anti-Parasitic Efficacy of RNAi Therapeutics

  CAMBRIDGE, Mass. -- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced the publication of a new study in Cell Host & Microbe on the role of a host gene, heme oxygenase-1 (HO-1), in the cause and pathway of malaria parasitic infection. The collaboration was led by...

  Articles 2008-05-21

• Alnylam to Webcast Presentation at the Bank of America 2008 Health Care Conference

  CAMBRIDGE, Mass. -- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the Bank of America 2008 Health Care Conference on Thursday, May 15, 2008, at 11:10 a.m. PT (2:10 p.m. ET) at the Four Seasons Hotel in Las...

  Articles 2008-05-13

• Alnylam to Webcast Presentation at the Rodman & Renshaw 5th Annual Global Healthcare Conference

  CAMBRIDGE, Mass. -- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the Rodman & Renshaw 5th Annual Global Healthcare Conference on Monday, May 19, 2008, at 11:50 a.m. CEST (5:50 a.m. ET) at Le Meridien Beach Plaza Hotel...

  Articles 2008-05-12

• Novartis Exercises Rights to Purchase Additional Shares of Alnylam's Common Stock in Accordance with Terms of Existing Investor Rights Agreement

  CAMBRIDGE, Mass. -- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that Novartis has elected to fully exercise its current right to purchase 213,888 unregistered shares of Alnylam's common stock in accordance with the terms of the Investor Rights Agreement between Alnylam and Novartis, dated September...

  Articles 2008-05-08

• Alnylam Pharmaceuticals Reports First Quarter 2008 Financial Results

  - Achieves Key Milestones Including Human Proof of Concept for an RNAi Therapeutic in GEMINI Phase II Study and New Partnerships on microRNA Therapeutics and RNAi Delivery - - Completes First Quarter with $444 Million in Cash and Strongest Revenues to Date of Over $22 Million - ...

  Articles 2008-05-08

• Regulus Therapeutics Exclusively Licenses Intellectual Property from Stanford University Relating to microRNA Antagonists to Treat Inflammatory Diseases

  CAMBRIDGE, Mass. & CARLSBAD, Calif. -- Regulus Therapeutics LLC, a joint venture between Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) formed to discover, develop, and commercialize microRNA miRNA therapeutics, announced today that it has obtained exclusive rights from Stanford University to worldwide patent applications covering methods...

  Articles 2008-05-06

• Alnylam to Webcast Conference Call Discussing First Quarter 2008 Financial Results

  CAMBRIDGE, Mass. -- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that it will report financial results for the first quarter of 2008 on Thursday, May 8, 2008, after the U.S. financial markets close. Management will provide an update on the company, discuss first...

  Articles 2008-05-02

• Alnylam to Webcast Presentation at the Deutsche Bank 33rd Annual Health Care Conference

  CAMBRIDGE, Mass. -- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the Deutsche Bank 33rd Annual Health Care Conference on Tuesday, May 6, 2008, at 9:30 a.m. ET at the InterContinental Hotel in Boston, Mass. A...

  Articles 2008-04-30

• Alnylam and Collaborators Publish Research on the Immunostimulatory Properties and Mechanisms of Certain siRNAs in Mammalian Cells

  CAMBRIDGE, Mass. -- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced the publication of a study in the Journal of Interferon & Cytokine Research by scientists at Alnylam Europe now Roche Kulmbach, and collaborators, further delineating the mechanisms whereby some siRNAs can trigger immunostimulatory effects in...

  Articles 2008-04-28